Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 169 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Musculoskeletal Diseases or Conditions Clear all
Completed No phase listed Observational

National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions

NCT01322165
View directory record Official record
Conditions
Marfan Syndrome, Turner Syndrome, Ehlers-Danlos Syndrome, Loeys-Dietz Syndrome, FBN1, TGFBR1, TGFBR2, ACTA2 or MYH11 Genetic Mutation, Bicuspid Aortic Valve Without Known Family History, Bicuspid Aortic Valve With Family History, Bicuspid Aortic Valve With Coarctation, Familial Thoracic Aortic Aneurysm and Dissections, Shprintzen-Goldberg Syndrome, Other Aneur/Diss of Thoracic Aorta Not Due to Trauma, <50yo, Other Congenital Heart Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
3,706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
7
States / cities
Honolulu, Hawaii • Baltimore, Maryland • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Oct 2, 2026, 4:10 AM EDT
Not listed Not applicable Interventional

Cellular & Biocellular Regenerative Therapy in Musculoskeletal Pain, Dysfunction,Degenerative or Inflammatory Disease

NCT03090672
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Nodule, Degenerative Joint Disease, Tendinopathy, Tendinosis, Back Pain
Interventions
Normal Saline, Tissue Stromal Vascular Fraction, Platelet Rich Plasma, Cellular Stromal Vascular Fraction
Drug · Procedure · Biological
Lead sponsor
Robert W Alexander, MD
Other
Eligibility
18 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
North Attleboro, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 2, 2026, 4:10 AM EDT
Terminated No phase listed Observational

TITAN™ Reverse Shoulder System

NCT02204228
View directory record Official record
Conditions
Osteoarthritis of the Shoulder
Interventions
TITAN™ Reverse Shoulder System (TRS)
Device
Lead sponsor
Smith & Nephew, Inc.
Industry
Eligibility
21 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
7
States / cities
Gainesville, Florida • Columbia, Maryland • Starkville, Mississippi + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 4 Interventional Results available

Best Practice Using Rocuronium and Reversal With Neostigmine or Sugammadex

NCT03543826
View directory record Official record
Conditions
Muscle Weakness
Interventions
Protocol for rocuronium neuromuscular block
Combination Product
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Not applicable Interventional

Individualized Exercise Programs for Patients Receiving Chemotherapy for Newly Diagnosed Acute or Relapsed Myeloid Leukemia or Lymphoblastic Leukemia

NCT00499759
View directory record Official record
Conditions
Depression, Fatigue, Leukemia, Musculoskeletal Complications, Psychosocial Effects of Cancer and Its Treatment
Interventions
Resting vitals, Body Composition, Timed Get-up and Go test (TGUG)., Cardiorespiratory assessment, Handgrip evaluation, Dynamic muscular endurance
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 2 Interventional

Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout

NCT05253833
View directory record Official record
Conditions
Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
Interventions
AR882 Dose 1, AR882 Dose 2, Allopurinol Tablet
Drug
Lead sponsor
Arthrosi Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Not applicable Interventional

Evaluation of the Effectiveness of Transforaminal Epidural Injections in Lumbar Disc Herniation or Radiculitis

NCT01052571
View directory record Official record
Conditions
Low Back Pain
Interventions
lumbar transforaminal epidural injections
Procedure
Lead sponsor
Pain Management Center of Paducah
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Paducah, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Oct 2, 2026, 4:10 AM EDT
Recruiting Not applicable Interventional

Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed With Autograft in Patients Undergoing Posterolateral Lumbar Fusion

NCT04679844
View directory record Official record
Conditions
Degenerative Disc Disease, Spine Fusion, Back Pain
Interventions
MagnetOs Easypack Putty, Demineralized Bone Matrix or Fibers mixed with local autograft bone
Device
Lead sponsor
Kuros Biosurgery AG
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Irvine, California • Grand Rapids, Michigan • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Sirolimus for Autoimmune Disease of Blood Cells

NCT00392951
View directory record Official record
Conditions
Autoimmune Pancytopenia, Autoimmune Lymphoproliferative Syndrome (ALPS), Evans Syndrome, Idiopathic Thrombocytopenic Purpura, Anemia, Hemolytic, Autoimmune, Autoimmune Neutropenia, Lupus Erythematosus, Systemic, Inflammatory Bowel Disease, Rheumatoid Arthritis
Interventions
sirolimus
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of Wafermine™ for Post-bunionectomy or Abdominoplasty Pain

NCT03246971
View directory record Official record
Conditions
Acute Pain, Bunion, Abdominoplasty
Interventions
Wafermine™ 50 mg, Wafermine™ 75 mg, Placebos, Wafermine™ 25 mg
Drug
Lead sponsor
iX Biopharma Ltd.
Other
Eligibility
18 Years to 75 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 3 Interventional

Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003

NCT02289716
View directory record Official record
Conditions
Osteoarthritis, Pain
Interventions
Placebo, Fulranumab 1 mg, Fulranumab 3 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
El Cajon, California • Sherman Oaks, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 2, 2026, 4:10 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

NCT04806620
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Autoimmune Encephalitis, Celiac Disease, Celiac Disease in Children, Chronic Lyme Disease, Post-treatment Lyme Disease Syndrome, Crohn's Disease, Dysautonomia, Anorexia Nervosa, Bulimia Nervosa, ARFID, Avoidant / Restrictive Food Intake Disorder, Ehlers Danlos Syndrome, Endometriosis, Fibromyalgia (FM), Long COVID, Lupus, Migraines, Mast Cell Activation Syndrome, Multiple Sclerosis, Myalgic Encephalomyelitis (ME), Myasthenia Gravis, Generalized, Myasthenia Gravis in Children, Narcolepsy, Obsessive Compulsive Disorder (OCD), PANDAS, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), POTS - Postural Orthostatic Tachycardia Syndrome, General Anxiety Disorder, Social Anxiety Disorder, PTSD - Post Traumatic Stress Disorder, Psoriasis, Traumatic Brain Injury, Tourette's Syndrome, Inflammatory Bowel Disease (IBD), Autoimmune Diseases, Neurological Diseases or Conditions, Psychiatric Disorder, Sjogren&#39;s Syndrome, Ulcerative Colitis and Crohn&#39;s Disease
Interventions
Not listed
Lead sponsor
Brain Inflammation Collaborative
Other
Eligibility
2 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
Delafield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites

NCT02436876
View directory record Official record
Conditions
Bacterial Infection
Interventions
MBN-101, Placebo
Drug · Other
Lead sponsor
Microbion Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Oct 2, 2026, 4:10 AM EDT
Recruiting No phase listed Observational

Clonal Hematopoiesis Chemotherapy and Radiation Effects Study

NCT07675967
View directory record Official record
Conditions
Lung Cancer (Diagnosis), Osteochondroma, Spitz Nevus, Solid Cancers, Breast Cancer, Gastric (Stomach) Cancer, Colorectal (Colon or Rectal) Cancer, Sarcoma, Ovarian Adenocarcinoma, Uterine Adenocarcinoma, Endometrial Adenocarcinoma, Esophageal Adenocarcinoma, Head and Neck Cancer, Therapy-Related Acute Myeloid Leukemia, Therapy-Related MDS, Clonal Hematopoiesis of Indeterminate Potential (CHIP), Clonal Cytopenia of Undetermined Significance
Interventions
Samples
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Not applicable Interventional

Interscalene Bupivacaine With Either Liposomal Bupivacaine or Continuous Peripheral Nerve Block for Shoulder Arthroscopy

NCT03816982
View directory record Official record
Conditions
Shoulder Pain
Interventions
Single-injection bupivacaine HCl plus liposomal bupivacaine, Single-injection bupivacaine HCl plus a subsequent bupivacaine CISB
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 2 Interventional

Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia

NCT00995618
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
Tranilast, Febuxostat, Combination - Tranilast and Febuxostat
Drug
Lead sponsor
Nuon Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Honolulu, Hawaii • Evansville, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2011 · Synced Oct 2, 2026, 4:10 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis

NCT04160091
View directory record Official record
Conditions
Osteoarthritis of the Shoulder, Adhesive Capsulitis
Interventions
FX006, Normal Saline
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
35 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
27
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 3 Interventional Results available

Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee

NCT02528188
View directory record Official record
Conditions
Chronic Pain, Osteoarthritis, Hip, Osteoarthritis, Knee
Interventions
NSAID, Tanezumab 2.5 mg, Tanezumab 5 mg
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
3,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
299
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 187 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 2, 2026, 4:10 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Non-invasive BCI-controlled Assistive Devices

NCT05183152
View directory record Official record
Conditions
Motor Disorders, Healthy, Spinal Cord Injuries, Muscular Diseases, Motor Neuron Disease, Stroke, Traumatic Brain Injury, Movement Disorders, Multiple Sclerosis
Interventions
NMES Feedback, Visual Feedback, TESS
Device
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 2, 2026, 4:10 AM EDT
Recruiting Not applicable Interventional

Influence of Antiseptic Washes on Wound Healing Complications After THA

NCT07104084
View directory record Official record
Conditions
Hip Osteoarthritis, Avascular Necrosis of Femur Head
Interventions
lavage chlorhexidine, lavage povidone-iodine
Device
Lead sponsor
F. Johannes Plate
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Monroeville, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Not applicable Interventional

Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome

NCT00010400
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome
Interventions
Cyclophosphamide, filgrastim
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 3 Interventional

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

NCT06588296
View directory record Official record
Conditions
Psoriatic Arthritis, Obesity
Interventions
Ixekizumab, Tirzepatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
81
States / cities
Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Catalyst CSR Shoulder System for Semi or Total Shoulder Arthroplasty

NCT04968405
View directory record Official record
Conditions
Osteoarthritis Shoulder, Avascular Necrosis of the Head of Humerus, Rheumatoid Arthritis Shoulder
Interventions
Catalyst CSR Total Shoulder System
Device
Lead sponsor
Catalyst OrthoScience
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
3
States / cities
Royal Oak, Michigan • Portland, Oregon • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Actis Total Hip System 2 Year Follow-up

NCT02783274
View directory record Official record
Conditions
Osteoarthritis, Traumatic Arthritis, Rheumatoid Arthritis, Congenital Hip Dysplasia, Avascular Necrosis of the Femoral Head, Acute Traumatic Fracture of the Femoral Head or Neck, Certain Cases of Ankylosis, Non-union of Femoral Neck Fractures, Certain High Sub-Capital & Femoral Neck Fractures in Elderly
Interventions
Actis Total Hip System
Device
Lead sponsor
DePuy Orthopaedics
Industry
Eligibility
21 Years and older
Enrollment
266 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
9
States / cities
Louisville, Kentucky • Boston, Massachusetts • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 2, 2026, 4:10 AM EDT